Due to different regulatory initiatives more oncology products are introduced earlier in the development process. Health economic evaluations based on e.g. one-armed Phase 1 and 2 clinical trials requires further innovation and development of health economic methods. The main issue discussed in this seminar is how to handle ‘uncertainty’ due to lack of long-term data at launch. Especially methods of extrapolation beyond trial as well as interpretations of sensitivity analyses will be discussed.
Invitation and program (pdf)